CO5650254A2 - Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa - Google Patents

Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa

Info

Publication number
CO5650254A2
CO5650254A2 CO05130352A CO05130352A CO5650254A2 CO 5650254 A2 CO5650254 A2 CO 5650254A2 CO 05130352 A CO05130352 A CO 05130352A CO 05130352 A CO05130352 A CO 05130352A CO 5650254 A2 CO5650254 A2 CO 5650254A2
Authority
CO
Colombia
Prior art keywords
alkyl
ring
replaced
aryl
sulfonylmetil
Prior art date
Application number
CO05130352A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5650254(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5650254A2 publication Critical patent/CO5650254A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

1.- Un compuesto de la fórmula (I)o una sal farmacéuticamente aceptable, profármaco o solvato de aquella, donde el anillo B representa un anillo arilo monocíclico que contiene seis átomos en el anillo o un anillo monocíclico heteroarilo que contiene hasta seis átomos en el anillo y contiene uno o más heteroátomos en el anillo donde cada uno de dicho heteroátomo es nitrógeno;R2 representa un grupo seleccionado de alquilo C1-6 o arilo, donde tal grupo se sustituye por uno o más grupos flúor;n es 1, 2 o 3; yR1 representa un grupo opcionalmente substituido seleccionado de alquilo C1-6, cicloalquilo C5-7, heterocicloalquilo, arilo, heteroarilo, alquilo C1-6-arilo, alquilo C1-6-heteroarilo, alquilo C1-6-cicloalquilo o alquilo C1-6-heterocicloalquilo.
CO05130352A 2003-06-27 2005-12-27 Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa CO5650254A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
CO5650254A2 true CO5650254A2 (es) 2006-06-30

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05130352A CO5650254A2 (es) 2003-06-27 2005-12-27 Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa

Country Status (34)

Country Link
US (1) US7485644B2 (es)
EP (1) EP1644340B1 (es)
JP (1) JP4701167B2 (es)
KR (1) KR20060026440A (es)
CN (2) CN1812974B (es)
AR (1) AR044931A1 (es)
AT (1) ATE414063T1 (es)
AU (1) AU2004251104B2 (es)
BR (1) BRPI0411929A (es)
CA (1) CA2529468A1 (es)
CO (1) CO5650254A2 (es)
CY (1) CY1108757T1 (es)
DE (1) DE602004017733D1 (es)
DK (1) DK1644340T3 (es)
ES (1) ES2315675T3 (es)
HK (1) HK1086835A1 (es)
HR (1) HRP20090009T3 (es)
IL (1) IL172615A0 (es)
IS (1) IS8257A (es)
MX (1) MXPA05013460A (es)
MY (1) MY138680A (es)
NO (1) NO20060444L (es)
NZ (1) NZ544208A (es)
PL (1) PL1644340T3 (es)
PT (1) PT1644340E (es)
RU (1) RU2351595C2 (es)
SA (1) SA04250224B1 (es)
SE (1) SE0301922D0 (es)
SI (1) SI1644340T1 (es)
TW (1) TW200524898A (es)
UA (1) UA81491C2 (es)
UY (1) UY28387A1 (es)
WO (1) WO2005000822A1 (es)
ZA (1) ZA200510458B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
CA2623879C (en) * 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
DK2597084T3 (en) * 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
WO2001062742A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
US7119203B2 (en) * 2002-04-25 2006-10-10 Pharmacia Corporation Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2528317A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
AU2004251104B2 (en) 2008-05-08
CA2529468A1 (en) 2005-01-06
ZA200510458B (en) 2007-03-28
US20070197542A1 (en) 2007-08-23
CY1108757T1 (el) 2014-04-09
PT1644340E (pt) 2009-01-02
TW200524898A (en) 2005-08-01
MXPA05013460A (es) 2006-03-09
MY138680A (en) 2009-07-31
SI1644340T1 (sl) 2009-02-28
HK1086835A1 (en) 2006-09-29
CN1812974A (zh) 2006-08-02
CN1812974B (zh) 2011-06-29
UA81491C2 (en) 2008-01-10
ATE414063T1 (de) 2008-11-15
EP1644340A1 (en) 2006-04-12
AR044931A1 (es) 2005-10-12
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
SE0301922D0 (sv) 2003-06-27
JP2007516164A (ja) 2007-06-21
NO20060444L (no) 2006-03-22
JP4701167B2 (ja) 2011-06-15
BRPI0411929A (pt) 2006-08-15
DE602004017733D1 (de) 2008-12-24
AU2004251104A1 (en) 2005-01-06
WO2005000822A1 (en) 2005-01-06
UY28387A1 (es) 2005-01-31
RU2351595C2 (ru) 2009-04-10
RU2005141058A (ru) 2006-07-27
PL1644340T3 (pl) 2009-04-30
EP1644340B1 (en) 2008-11-12
IL172615A0 (en) 2006-04-10
ES2315675T3 (es) 2009-04-01
DK1644340T3 (da) 2009-02-02
KR20060026440A (ko) 2006-03-23
CN102229589A (zh) 2011-11-02
US7485644B2 (en) 2009-02-03
HRP20090009T3 (en) 2009-02-28
IS8257A (is) 2006-01-23

Similar Documents

Publication Publication Date Title
AR036046A1 (es) Inhibidores de la hiv proteasa, composiciones que las contienen y sus usos farmaceuticos
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20050232A1 (es) Metodo y composiciones para tratar la artritis reumatoide
ES2436020T3 (es) Derivados de sulfonamida sustituidos
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
ES2167959T3 (es) Nafto(2,1-b)piranos fotocromicos fusionados con indeno.
PE20090042A1 (es) Analogos de ciclopamina
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
AR048377A1 (es) Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
EA201000101A1 (ru) Производные пиримидина 934
ES2518316T3 (es) Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
CO5650254A2 (es) Compuestos n-[4-sustituido piperazin-1-sulfonilmetil-alquil]-n-hidroxiformamida como inhibidores de metaloproteinasa
CO5650235A2 (es) Derivados de imidazol
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR042910A1 (es) Compuestos de pirazolopirimidina y procedimiento para preparar el mismo y composiciones farmaceuticas que los contienen
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
PE20020426A1 (es) ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed